Sentences with phrase «cell therapies hold»

While stem cell therapies hold promise for the treatment of a variety of serious diseases, for most conditions, these treatments are still years in the future.

Stem cell therapies hold great promise in treating a variety of diseases, but in order to develop them researchers must first be able to monitor them inside the body.

«Stem cell therapies hold great promise,» he says, from possible treatments for brain disease to heart disease and age - related disorders.

New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.

«Stem cell therapy holds a lot of promise but it's limited by the harsh injury micro-environment, which is frequently inflamed,» says Das.

For those patients who suffer from heart failure symptoms with no other option for treatment, stem cell therapy holds the potential to provide a better quality of life.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy.

The Wyss team believes the ability of the human gut - on - a-chip to culture the microbiome with human gut cells also holds promise for the field of precision medicine, where a patient's own cells and gut microbiota could one day be cultured inside a gut - on - a-chip for testing different therapies and identifying an individualized treatment strategy.

Then immunotherapy firm Juno Therapeutics shook hands with gene - editing start - up Editas to create anticancer immune cell therapies; Vertex Pharmaceuticals and Crispr Therapeutics, another start - up, inked an agreement that could be valued at $ 2.6 billion; while Regeneron Pharmaceuticals formed a patent licence agreement with ERS Genomics, which holds the rights to the foundational Crispr intellectual property from Emmanuelle Charpentier, one of the Crispr pioneers.

«Stem cell gene therapy could be key to treating Duchenne muscular dystrophy: Approach developed at UCLA holds promise for 60 percent of patients with the deadly disease.»

Stem cells hold tremendous promise as therapies, but experts say they are still experimental and are not ready to be widely deployed outside regulated and limited trials.

«We haven't held out much hope for immune therapy to work in them because before you can enter cancer cells to knock them down, you have to be able to get inside.

«If our predictions hold true, tumor cells with intact p53 may show the best response to therapy targeting the IGF - 1R signal; however, when p53 is not functioning normally, response to this therapy may not be as expected,» said Greenberg, the study's corresponding author.

San Diego, California, October 10, 2013 — ViaCyte, Inc. announced today that an update on the Company's progress toward a transformative stem cell - derived cell therapy for the treatment of type 1 diabetes will be presented at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14 - 16 in La Jolla, Califorcell - derived cell therapy for the treatment of type 1 diabetes will be presented at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14 - 16 in La Jolla, Califorcell therapy for the treatment of type 1 diabetes will be presented at the 3rd Annual Regen Med Partnering Forum, part of the 2013 Stem Cell Meeting on the Mesa to be held October 14 - 16 in La Jolla, CaliforCell Meeting on the Mesa to be held October 14 - 16 in La Jolla, California.

SAN DIEGO and BETHESDA, MD, March 3, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Eugene Brandon, Director of Strategic Relations and Project Management, at the JDRF TypeOneNation Summit.

SAN DIEGO, April 20, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced four presentations at upcoming healthcare events.

The insights we expect to gain from this study of mitochondria dysfunction and microRNAs, and what they tell us about how some RPE cells become diseased while neighboring cells are either resistant or susceptible to disease, hold promise of becoming the basis for entirely new therapies for individuals suffering from AMD, built upon nucleic acid - based treatments aimed at rejuvenating RPE cell mitochondria.

HLI, a privately held company headquartered in San Diego, CA was founded in 2013 by pioneers in the fields of genomics and stem cell therapy.

Consequently, iPS cells hold great potential for use in regenerative therapies.

SAN DIEGO, April 12, 2018 — ViaCyte, Inc., a privately - held regenerative medicine company, today announced President and CEO, Paul Laikind, Ph.D., will present at Alliance for Regenerative Medicine's 6th Annual Cell & Gene Therapy Investor Day in New York.

SAN DIEGO, September 9, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced participation on a panel at the 2016 BioPharm ™ America — 9th Annual International Partnering Conference.

By sweeping away AS aggregates before they get a chance to spread, AS immunotherapies have the potential to hold the nonmotor symptoms of PD at bay, slowing the overall progress of the disease, and — when combined with mature cell therapy — eventually preventing the disease altogether, and potentially even reversing it.

Virtually identical to human embryonic stem cells (hESCs) except for their origin of isolation, the recently created induced pluripotent stem cells (iPSCs)(Yu et al., 2007; Takahashi et al., 2007) hold much potential for use in regenerative therapies.

SAN DIEGO, March 17, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced a presentation by Dr. Paul Laikind, President and CEO, at the third annual Regen Med Investor Day co-hosted by the Alliance for Regenerative Medicine (ARM) and top financial firm Piper Jaffray.

San Diego, January 8, 2015 — ViaCyte, Inc., a privately - held regenerative medicine company with the first stem cell - derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company's Phase 1/2 clinical trial of its VC - 01TM product candidate.

Targeted gene therapy, which would affect smooth muscle cells but not skeletal muscle, holds promise for treatment of these and other disorders.

San Diego, California, October 6, 2014 — ViaCyte, Inc., a privately - held regenerative medicine company developing a stem cell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follcell - derived islet replacement therapy for the treatment of diabetes, called VC - 01 ™, will give two presentations at the annual Stem Cell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follCell Meeting on the Mesa Conference, being held at the Estancia La Jolla Hotel & Spa and The Salk Institute for Biological Studies, as follows:

ViaCyte is a privately - held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

SAN DIEGO, March 1, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced presentations at the JDRF TypeOneNation Summit meetings being held in Washington DC and Los Angeles.

Partial clinical hold on high dose SGT - 001 resolved, additional information requested on full clinical hold NIH grant will further development of replacement beta cells for type 1 and type 2 diabetes New trial will assess MSCs to improve heart function in heart failure patients ReNeuron wins grant for retinal cell therapy development

«It has been rewarding to be a part of a company that has pioneered the development of stem cell therapy, including the development of technologies that hold promise for the treatment of diabetes,» said Lewis.

San Diego, August 1, 2017 — ViaCyte, Inc., a privately - held, leading regenerative medicine company, announced today that the first patients have been implanted with the PEC - Direct ™ product candidate, a novel islet cell replacement therapy in development as a functional cure for patients with type 1 diabetes who are at high risk for acute life - threatening complications.

Next week, he will be the keynote speaker at the 2015 Conference on Cell and Gene Therapy for HIV Cure held Aug. 13 - 14 at Fred Hutch.

SAN DIEGO, June 22, 2016 — ViaCyte, Inc., a privately - held regenerative medicine company with the first pluripotent stem cell - derived islet replacement therapy for the treatment of diabetes in clinical - stage development, today announced two presentations at ISSCR 2016 Annual Meeting.

ViaCyte is a privately held, clinical - stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.

He also holds certification in Stem Cell Therapy and K - Laser Therapeutic Laser.

The FDA - cleared low level laser therapy (LLLT) technology is applied with a hand - held applicator providing targeted super pulsed laser light that stimulates cell regeneration.

Although more research is needed, stem cell - based therapies hold promise for a wide range of diseases affecting all animal species.